Clinical Hematology International

<Previous Article In Issue
Volume 2, Issue 1, March 2020, Pages 35 - 39

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma

Authors
Kristian T. Andersen1, *, Maja Hinge1, Agoston Gyula Szabo1, Erik Segel2, Tina Ormstrup3, Paw C. Holdgaard4, Niels Pallisgaard5, Gitte Kerndrup6, Torben Plesner1
1Department of Medicine, Division of Hematology, Lillebælt Hospital, Vejle, Denmark; Department of Regional Health Research (IRS) at the University of Southern Denmark (SDU), Odense, Denmark
2Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
3Department of Radiology, Lillebælt Hospital, Vejle, Denmark
4Department of Nuclear Medicine, Lillebælt Hospital, Vejle, Denmark
5Department of Clinical Immunology and Biochemistry, Lillebælt Hospital, Vejle, Denmark
6Department of Clinical Genetics, Lillebælt Hospital, Vejle, Denmark
*Corresponding author. Email: Kristian.Thidemann.Andersen@rsyd.dk
Corresponding Author
Kristian T. Andersen
Received 4 October 2019, Accepted 15 January 2020, Available Online 26 January 2020.
DOI
10.2991/chi.d.200116.001How to use a DOI?
Keywords
Multiple myeloma; Clinical trial; Hematology; First line therapy
Copyright
© 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue
Journal
Clinical Hematology International
Volume-Issue
2 - 1
Pages
35 - 39
Publication Date
2020/01/26
ISSN (Online)
2590-0048
DOI
10.2991/chi.d.200116.001How to use a DOI?
Copyright
© 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

risenwbib
TY  - JOUR
AU  - Kristian T. Andersen
AU  - Maja Hinge
AU  - Agoston Gyula Szabo
AU  - Erik Segel
AU  - Tina Ormstrup
AU  - Paw C. Holdgaard
AU  - Niels Pallisgaard
AU  - Gitte Kerndrup
AU  - Torben Plesner
PY  - 2020
DA  - 2020/01/26
TI  - Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
JO  - Clinical Hematology International
SP  - 35
EP  - 39
VL  - 2
IS  - 1
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.200116.001
DO  - 10.2991/chi.d.200116.001
ID  - Andersen2020
ER  -